LATEST NEWS: 27 October 2026 Findings from the AGITG/TROG 18.04 MASTERPLAN trial provide crucial new evidence that adding stereotactic body radiotherapy (SBRT) to chemotherapy is beneficial in patients with high-risk localised pancreatic cancer. Results from the multicentre phase 2 study were simultaneously published in the Lancet Oncology journal and
LATEST NEWS: 14 October 2026 Adding a FET-PET brain scan to standard magnetic resonance imaging (MRI) scans could help with planning targeted radiation therapy after surgery in adult patients with newly diagnosed glioblastoma, new TROG trial findings show. The promising findings from the FET-PET in Glioblastoma (FIG) – TROG
LATEST NEWS: 16 July 2026 Secondary analysis of data from the TROG 08.03 RAVES randomised phase III trial has provided valuable evidence to inform discussions about the timing of post-prostatectomy radiotherapy. The analysis, published in European Urology Oncology (as Article in Press), examined self-reported quality of life data among
LATEST NEWS: 15 July 2026 The TROG 18.01 NINJA trial has achieved the milestone of successfully completing participant recruitment, paving the way for improvements in radiation therapy treatment for prostate cancer. The final participant was recruited by Canberra Hospital in July. There are now a total of 472 men
LATEST NEWS: 20 MAY A number of TROG trials and projects garnered international attention this month, as researchers presented findings at one of the world’s largest radiotherapy and oncology meetings, ESTRO26. Congratulations to the many TROG Members and research teams who contributed to the European Society of Radiotherapy and
LATEST NEWS: 18 MAY 2026 A new non-invasive form of radiation therapy achieves unprecedented 100% effectiveness in treating primary kidney cancers, findings from the world-leading TROG 15.03/ANZUP 16001 FASTRACK II trial reveal. The long-term findings from the phase II multi-centre trial suggest the rapidly emerging Stereotactic Ablative Body Radiation
LATEST NEWS: 27 January 2026 New guidelines to ensure accuracy and quality in clinical trials using stereotactic radiosurgery (SRS) to treat brain metastases have been published, after being developed by a TROG Working Group. The use of SRS for treating brain metastases has increased rapidly. SRS delivers very high
LATEST NEWS: 25 November 2025 Vital quality assurance (QA) processes used in radiation therapy (RT) clinical trials could be automated in the future, to reduce resource and time demands on clinicians and researchers, a new study involving a TROG Cancer Research trial has revealed. Quality assurance is a vital
LATEST NEWS: 6 November 2025 Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, according to 10-year follow-up from an international trial on which TROG collaborated Findings from the BIG 2-04/MRC/TROG 11.01 SUPREMO trial were
TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer with Stereotactic Ablative Body Radiotherapy (SABR) is both more effective and less expensive than traditional ablative therapies in Australia, according to a new economic analysis of TROG 15.03/ANZUP 16001 FASTRACK II trial data. The findings of the economic evaluation, published
